MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
McCoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Pope B, Georgeson P, Hong MKH, Kurganovs N, Lunke S, Clarkson MJ, Cmero M, Kerger M, Stuchbery R, Chow K, Haviv I, Ryan A, Costello AJ, Corcoran NM, Hovens CM.
McCoy P, et al. Among authors: clarkson mj.
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1167-1180. doi: 10.1038/s41391-021-00379-4. Epub 2021 Jun 9.
Prostate Cancer Prostatic Dis. 2021.
PMID: 34108644